9 – Conclusion and perspectives
The clinical management of elderly patients with myeloma remains challenging. In addition to up-to-date knowledge of tumor biology and of treatment strategies, day-to-day practice requires an accurate assessment of many clinical and social parameters. The use of standardized frailty assessments needs to be validated in a community-based and prospective setting. Novel agents including thalidomide, lenalidomide, and bortezomib have helped to improve the outcome for elderly myeloma patients. To improve the outcome further, priority should be given to developing more effective treatment strategies and clinical trials tailored to the specific needs of these patients.
All topics within this chapter
3. Biological and clinical features
4. Defining aims
5. What to aim for?
6. Disease-specific treatment options
7. Tailoring the treatment to the patient
8. Supportive care
9. Conclusion and perspectives
Chapter 1 – Pathophysiology
Chapter 2 – Diagnosis and staging
Chapter 3 – Treatment of transplant-eligible patients
Chapter 4 – Treatment of elderly patients with myeloma
Chapter 5 – Treatment of relapsed multiple myeloma
Chapter 6 – Bone disease